Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context
Summary: Background: Photoimmunotherapy (PIT) is a potent modality for cancer treatment. The conventional PIT regimen involves the systemic delivery of an antibody–photoabsorber conjugate, followed by a 24-h waiting period to ensure adequate localisation on the target cells. Subsequent exposure to...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425000106 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589965099270144 |
|---|---|
| author | Yuichi Adachi Kotaro Miyake Kika Ohira Shingo Satoh Kentaro Masuhiro Ryuya Edahiro Yuya Shirai Maiko Naito Yujiro Naito Takayuki Shiroyama Shohei Koyama Haruhiko Hirata Kota Iwahori Izumi Nagatomo Yoshito Takeda Atsushi Kumanogoh |
| author_facet | Yuichi Adachi Kotaro Miyake Kika Ohira Shingo Satoh Kentaro Masuhiro Ryuya Edahiro Yuya Shirai Maiko Naito Yujiro Naito Takayuki Shiroyama Shohei Koyama Haruhiko Hirata Kota Iwahori Izumi Nagatomo Yoshito Takeda Atsushi Kumanogoh |
| author_sort | Yuichi Adachi |
| collection | DOAJ |
| description | Summary: Background: Photoimmunotherapy (PIT) is a potent modality for cancer treatment. The conventional PIT regimen involves the systemic delivery of an antibody–photoabsorber conjugate, followed by a 24-h waiting period to ensure adequate localisation on the target cells. Subsequent exposure to near-infrared (NIR) light selectively damages the target cells. We aimed to improve the efficacy of PIT in vivo by evaluating the effects of the different routes of conjugate administration on treatment outcomes. Methods: Subcutaneous Lewis lung carcinoma tumours were established in mice, targeting cluster of differentiation (CD)44 with an anti-CD44 antibody conjugated to IRDye700DX (IR700). The conjugate was administered via the intravenous or intratumoural route followed by the assessment of antibody binding and therapeutic effects of PIT. Findings: Compared to intravenous administration, intratumoural delivery of the CD44-IR700 conjugate significantly increased the number of cells binding to the conjugate by >five-fold. This method, combined with NIR light irradiation, halved tumour growth when compared to intravenous delivery. Reducing the interval between intratumoural injection and NIR light exposure to 30 min did not diminish efficacy, thereby demonstrating the feasibility of a 1-h procedure. Interpretation: Intratumoural administration of the antibody–photoabsorber conjugate enhanced the efficacy of PIT in vivo. A simplified, 1-h procedure involving conjugate tumour injection followed by irradiation emerged as a potent cancer treatment strategy. Funding: This study was supported by the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, Japan Science and Technology Agency, and the Osaka Medical Research Foundation for Intractable Diseases. |
| format | Article |
| id | doaj-art-27235f852a214d8899b472058491ffbf |
| institution | Kabale University |
| issn | 2352-3964 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj-art-27235f852a214d8899b472058491ffbf2025-01-24T04:45:21ZengElsevierEBioMedicine2352-39642025-02-01112105566Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in contextYuichi Adachi0Kotaro Miyake1Kika Ohira2Shingo Satoh3Kentaro Masuhiro4Ryuya Edahiro5Yuya Shirai6Maiko Naito7Yujiro Naito8Takayuki Shiroyama9Shohei Koyama10Haruhiko Hirata11Kota Iwahori12Izumi Nagatomo13Yoshito Takeda14Atsushi Kumanogoh15Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Corresponding author. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan.Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, JapanDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Statistical Genetics, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Statistical Genetics, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, JapanDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan; Center for Infectious Diseases for Education and Research, Osaka University, Osaka, Japan; Japan Agency for Medical Research and Development – Core Research for Evolutional Science and Technology, Osaka University, Osaka, Japan; Center for Advanced Modalities and DDS, Osaka University, Osaka, Japan; Corresponding author. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan.Summary: Background: Photoimmunotherapy (PIT) is a potent modality for cancer treatment. The conventional PIT regimen involves the systemic delivery of an antibody–photoabsorber conjugate, followed by a 24-h waiting period to ensure adequate localisation on the target cells. Subsequent exposure to near-infrared (NIR) light selectively damages the target cells. We aimed to improve the efficacy of PIT in vivo by evaluating the effects of the different routes of conjugate administration on treatment outcomes. Methods: Subcutaneous Lewis lung carcinoma tumours were established in mice, targeting cluster of differentiation (CD)44 with an anti-CD44 antibody conjugated to IRDye700DX (IR700). The conjugate was administered via the intravenous or intratumoural route followed by the assessment of antibody binding and therapeutic effects of PIT. Findings: Compared to intravenous administration, intratumoural delivery of the CD44-IR700 conjugate significantly increased the number of cells binding to the conjugate by >five-fold. This method, combined with NIR light irradiation, halved tumour growth when compared to intravenous delivery. Reducing the interval between intratumoural injection and NIR light exposure to 30 min did not diminish efficacy, thereby demonstrating the feasibility of a 1-h procedure. Interpretation: Intratumoural administration of the antibody–photoabsorber conjugate enhanced the efficacy of PIT in vivo. A simplified, 1-h procedure involving conjugate tumour injection followed by irradiation emerged as a potent cancer treatment strategy. Funding: This study was supported by the Japan Society for the Promotion of Science, the Japan Agency for Medical Research and Development, Japan Science and Technology Agency, and the Osaka Medical Research Foundation for Intractable Diseases.http://www.sciencedirect.com/science/article/pii/S2352396425000106PhotoimmunotherapyIntratumoural administrationLung cancerAntibody–photoabsorber conjugate |
| spellingShingle | Yuichi Adachi Kotaro Miyake Kika Ohira Shingo Satoh Kentaro Masuhiro Ryuya Edahiro Yuya Shirai Maiko Naito Yujiro Naito Takayuki Shiroyama Shohei Koyama Haruhiko Hirata Kota Iwahori Izumi Nagatomo Yoshito Takeda Atsushi Kumanogoh Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context EBioMedicine Photoimmunotherapy Intratumoural administration Lung cancer Antibody–photoabsorber conjugate |
| title | Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context |
| title_full | Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context |
| title_fullStr | Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context |
| title_full_unstemmed | Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context |
| title_short | Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44–targeting antibody–photoabsorber conjugatesResearch in context |
| title_sort | enhancing the efficacy of near infrared photoimmunotherapy through intratumoural delivery of cd44 targeting antibody photoabsorber conjugatesresearch in context |
| topic | Photoimmunotherapy Intratumoural administration Lung cancer Antibody–photoabsorber conjugate |
| url | http://www.sciencedirect.com/science/article/pii/S2352396425000106 |
| work_keys_str_mv | AT yuichiadachi enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT kotaromiyake enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT kikaohira enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT shingosatoh enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT kentaromasuhiro enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT ryuyaedahiro enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT yuyashirai enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT maikonaito enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT yujironaito enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT takayukishiroyama enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT shoheikoyama enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT haruhikohirata enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT kotaiwahori enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT izuminagatomo enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT yoshitotakeda enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext AT atsushikumanogoh enhancingtheefficacyofnearinfraredphotoimmunotherapythroughintratumouraldeliveryofcd44targetingantibodyphotoabsorberconjugatesresearchincontext |